IGF-1 Storage, Stability, and Handling: What the Literature Describes
Published IGF-1 research overwhelmingly examines biology — muscle, cartilage, skin and longevity signaling — rather than vial stability. This page separates two evidence types: labeling for the approved recombinant IGF-1 product, which describes refrigerated storage and a limited in-use period, and general lyophilized-peptide chemistry, which describes why dry powder is more stable than solution, what freeze-thaw and light exposure do to proteins, and which visual changes are associated with degradation. It is descriptive only and contains no handling instructions.
Insulin-like growth factor 1 (IGF-1) is a 70-amino-acid polypeptide, and nearly all of the published literature about it concerns what it does in tissue rather than how a vial of it behaves on a shelf. Reviews have described IGF-1 signaling as a central regulator of skeletal muscle hypertrophy and atrophy (PMID 32858949), and separate work has reported IGF-1 involvement in skin endocrinology (PMID 39998423). Those papers describe biology, not storage conditions. This page collects storage, shelf-life and handling questions about IGF-1 into one place and is explicit, in every section, about whether a statement comes from IGF-1-specific sources or from general protein and lyophilized-peptide chemistry.
This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical decision. Nothing here is a protocol, and no statement below is directed at a reader as an action to perform.
Two Different Kinds of Evidence — and Why the Distinction Matters
When people ask how IGF-1 is stored, the answers in circulation come from at least three distinct sources, which are not interchangeable:
- Regulatory labeling for the approved recombinant IGF-1 product. Mecasermin, a recombinant human IGF-1 product approved in the United States for severe primary IGF-1 deficiency, carries storage language in its prescribing information. That language is specific to a formulated, preserved, sterile pharmaceutical solution.
- General lyophilized-peptide and protein stability chemistry. This body of knowledge describes why freeze-dried powders resist degradation, what hydrolysis, oxidation, deamidation and aggregation are, and how temperature and moisture influence them. It applies broadly to peptides and proteins, not uniquely to IGF-1.
- Supplier certificates of analysis and research-use-only documentation. These describe how a given lot was characterised and stored by that facility. They are lot-specific and are not peer-reviewed stability trials.
None of the peer-reviewed papers cited on this page is a stability study of IGF-1. The cited literature describes IGF-1 biology — for example, a cell study in which researchers reported that IGF-1 upregulated biglycan and decorin by increasing translation and reducing ADAMTS5 expression (PMID 33573338). Where this page describes temperature ranges or degradation mechanisms, those descriptions come from labeling and general protein chemistry, and are flagged as such rather than dressed up as IGF-1-specific trial findings.
Lyophilized Powder Versus Reconstituted Solution
General protein chemistry draws a sharp line between a dry, freeze-dried (lyophilized) peptide and the same peptide dissolved in liquid. In the dry state, water — the reactant in hydrolysis and a mobility requirement for most degradation chemistry — has largely been removed, and molecular motion is restricted. Lyophilized peptide powders are therefore described in general pharmaceutical literature as substantially more stable than aqueous solutions of the same molecule, which is the reason research peptides are distributed as powders in the first place.
Once a powder is dissolved, several general degradation routes become available to a protein of IGF-1's size and composition: hydrolysis of peptide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine residues, disulfide scrambling in molecules that contain cysteine bridges, and physical aggregation at air–liquid interfaces. IGF-1 contains three intramolecular disulfide bonds, which is a structural fact about the molecule rather than a study finding, and disulfide-containing proteins are generally described as sensitive to pH extremes and to agitation. Again: this is general chemistry, not an IGF-1 stability experiment.
Refrigeration in Product Labeling
Prescribing information for the approved recombinant human IGF-1 product describes refrigerated storage between 2 °C and 8 °C, instructs that the product not be frozen, directs that it be protected from direct light, and states that a vial is to be discarded 30 days after first use. Those parameters belong to that specific formulated product and its preservative system. They are reported here as a regulatory fact about an approved medicine, not as a general rule for research material, and not as guidance for any reader.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeShelf Life and Expiry: What the Terms Mean
In pharmaceutical practice, an expiry date is a manufacturer's attestation, supported by that manufacturer's own stability data, that a product met its specifications through that date under the labeled storage conditions. It is not a prediction that the molecule vanishes the following morning, and it is not transferable between products or between storage conditions. Research-use-only peptide material frequently carries a manufacturer-assigned retest or recommended-use date derived from accelerated stability testing rather than from a published clinical trial.
General lyophilized-peptide literature describes dry powder stored cold and sealed as retaining specification for periods typically measured in months to years, with the actual figure depending on the specific sequence, residual moisture, container closure, and the presence of excipients such as mannitol or bulking agents. Because those variables differ by lot and by facility, general chemistry cannot supply a single number for IGF-1, and this page does not assign one.
Storage States Compared
| State | What general chemistry or labeling describes | Source type |
|---|---|---|
| Sealed lyophilized powder, refrigerated | Dry state limits hydrolysis and molecular mobility; generally described as the most stable presentation for peptides | General lyophilized-peptide chemistry |
| Lyophilized powder, room temperature | Degradation chemistry proceeds faster at higher temperature; residual moisture and light exposure are additional variables | General protein chemistry |
| Reconstituted aqueous solution | Hydrolysis, deamidation, oxidation and aggregation pathways become accessible; refrigerated storage and limited in-use windows are typical of labeled protein products | Labeling for approved recombinant IGF-1 product |
| Frozen solution | Freezing arrests most chemical degradation but introduces ice-interface and concentration stresses; repeated freeze–thaw cycling is generally described as damaging to proteins | General protein chemistry |
| Approved product vial, in use | Labeled for 2–8 °C, protection from light, no freezing, and discard 30 days after first use | Regulatory labeling |
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appRoom Temperature and Transit
Peptides are routinely shipped without active refrigeration, and general stability literature explains why: lyophilized powders tolerate short ambient excursions far better than solutions, because the rate-limiting degradation chemistry requires water and molecular mobility. Cold-chain shipping with gel packs or dry ice is used for solutions, for labile molecules, and for material intended for long-term reference storage. Nothing in the peer-reviewed IGF-1 literature cited here characterises transit excursions for IGF-1 specifically; the laboratory studies that used IGF-1 — for instance, the work in which researchers reported that IGF-1 upregulated proteoglycan expression in cultured cells (PMID 33573338) — described biological endpoints and not vial-handling variables.
Air travel introduces separate, non-scientific considerations: national carry-on liquid rules, customs declarations for biological material, and, in the United States, the fact that research-use-only material is not a prescription medicine and is not labeled for human administration. Those are regulatory and legal matters rather than stability questions.
Freezing and Freeze–Thaw Cycles
General protein chemistry describes freezing as a trade-off. Low temperature slows essentially all chemical degradation, which is why long-term reference stocks of proteins are often held frozen, frequently in single-use aliquots. The costs are physical: ice crystal formation creates large ice–water interfaces at which proteins can unfold, freeze-concentration raises local solute concentration and can shift pH as buffer components crystallise, and each thaw–refreeze cycle repeats those stresses. Repeated freeze–thaw cycling is consistently described in general protein literature as a driver of aggregation and loss of activity. Labeling for the approved recombinant IGF-1 product, by contrast, directs that the formulated solution not be frozen at all — an illustration of how formulation-specific instructions can differ from generic laboratory practice.
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeSigns of Degradation Described in Protein Chemistry
General protein and peptide literature associates several observable changes with loss of integrity, while also cautioning that visual inspection is a crude instrument and that a solution can be substantially degraded while still appearing normal:
- Visible particulates, haze or cloudiness in a solution that was previously clear, generally attributed to aggregation or to microbial contamination.
- Colour change or yellowing of a powder or solution.
- A cake that has collapsed, melted, shrunk or shifted inside the vial, which in lyophilized products is generally interpreted as evidence of a temperature excursion or moisture ingress.
- Loss of vacuum or a compromised stopper seal, which permits moisture and oxygen entry.
- Failure to dissolve cleanly, or persistent undissolved material.
Analytical methods — reverse-phase HPLC, size-exclusion chromatography, mass spectrometry and bioassay — are what stability programmes actually rely on, because they detect the deamidated, oxidised and aggregated species that the eye cannot see. Certificates of analysis from a manufacturing facility typically report purity by one or more of these methods for a specific lot at the time of release, not at the time of use.
How Handling Appears in Published IGF-1 Research
Experimental IGF-1 papers generally state the source and formulation of the peptide in their methods without treating storage as a study variable. The published work spans cell culture, animal models and mechanistic review: researchers reported that aerobic and resistance exercise alleviated skeletal muscle atrophy through the IGF-1/IGF-1R–PI3K/Akt pathway in mice following myocardial infarction (PMID 34852207); a separate cancer-biology study reported that the fungal immunomodulatory protein rFIP-GMI suppressed IGF-1-induced invasion and migration in breast cancer cells via PI3K/Akt/β-catenin inhibition (PMID 41294378); and an osteoarthritis study examined doxycycline combined with IGF-1 as a disease-modification strategy (PMID 41401641). Work on reduced IGF-1 signaling and longevity has reported that the lifespan effect depended on mitochondrial genome stability (PMID 40501628) — a use of the word "stability" that refers to genomes, not to vials, and one that is frequently confused in secondary summaries.
The practical implication of that literature landscape is narrow and worth stating plainly: anyone asserting a precise number of days or months of IGF-1 stability at a given temperature is drawing on manufacturer documentation or on general peptide chemistry, not on a published IGF-1 stability trial, and the distinction should be visible in how the claim is sourced.
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeRelated Reading
References
- Mechanisms of IGF-1-Mediated Regulation of Skeletal Muscle Hypertrophy and Atrophy (Cells, 2020)
- IGF-1 Upregulates Biglycan and Decorin by Increasing Translation and Reducing ADAMTS5 Expression (International Journal of Molecular Sciences, 2021)
- Aerobic exercise and resistance exercise alleviate skeletal muscle atrophy through IGF-1/IGF-1R-PI3K/Akt pathway in mice with myocardial infarction (American Journal of Physiology. Cell Physiology, 2022)
- rFIP-GMI Suppresses IGF-1-Induced Invasion and Migration in Breast Cancer Cells via PI3K/Akt/β-Catenin Inhibition (Drug Development Research, 2025)
- Doxycycline and IGF-1 as a synergistic combination therapy for OA disease modification (Biomedicine & Pharmacotherapy, 2026)
- The longevity effects of reduced IGF-1 signaling depend on the stability of the mitochondrial genome (bioRxiv, 2025)
- Endocrine Controls of Skin Aging (Endocrine Reviews, 2025)
Frequently asked questions
Is there a published stability study for IGF-1 specifically?▾
Not within the peer-reviewed set cited on this page. The IGF-1 literature referenced here addresses biology — for example, a review of IGF-1 signaling in muscle hypertrophy and atrophy (PMID 32858949) and a cell study reporting IGF-1 effects on biglycan and decorin (PMID 33573338). Storage temperatures and shelf-life figures come from product labeling and general lyophilized-peptide chemistry, which are different evidence types.
Why is lyophilized powder described as more stable than solution?▾
General protein chemistry attributes it to the removal of water and the restriction of molecular motion. Hydrolysis requires water, and deamidation, oxidation and aggregation all proceed faster when molecules move freely in solution. This is a broad principle across peptides and proteins, not an IGF-1-specific experimental finding, and it explains why research peptides are distributed as freeze-dried powders.
What does the approved IGF-1 product's labeling say about storage?▾
Prescribing information for the approved recombinant human IGF-1 product describes refrigerated storage between 2 °C and 8 °C, protection from direct light, no freezing, and discarding a vial 30 days after first use. That is a regulatory fact about a specific formulated, preserved pharmaceutical solution. It is not guidance for any reader and does not transfer to research-use-only material.
What does general chemistry say about freeze-thaw cycles?▾
Freezing slows chemical degradation, which is why long-term protein stocks are often held frozen in single-use aliquots. The physical costs described in general protein literature include unfolding at ice-water interfaces, freeze-concentration of solutes, and pH shifts as buffer components crystallise. Repeated cycling is consistently associated with aggregation and loss of activity across proteins generally.
What visual changes are associated with degradation?▾
General protein literature associates haze, visible particulates, yellowing, a collapsed or shifted lyophilized cake, a compromised stopper seal, and failure to dissolve cleanly with loss of integrity. The same literature cautions that appearance is insensitive: analytical methods such as HPLC, size-exclusion chromatography and mass spectrometry detect degradation products that inspection cannot.
Do IGF-1 studies report how the peptide was stored?▾
Methods sections typically name a source and formulation without treating storage as a study variable. Examples include a mouse study reporting exercise effects through the IGF-1/IGF-1R-PI3K/Akt pathway after myocardial infarction (PMID 34852207) and an osteoarthritis study combining doxycycline with IGF-1 (PMID 41401641). Neither measured vial stability as an outcome.
Does "IGF-1 stability" in longevity papers refer to storage?▾
No. A 2025 preprint reported that the longevity effects of reduced IGF-1 signaling depended on the stability of the mitochondrial genome (PMID 40501628). That use of "stability" describes genomic integrity within cells, not the physical or chemical stability of peptide material in a container. The two meanings are frequently conflated in secondary summaries.
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.